ERC/Mesothelin as a marker for chemotherapeutic response in patients with mesothelioma

Anticancer Research

Volumn 28, Issue 6 B, 2008, Pages 3933-3936

  Tajima, Ken ^a   Hirama, Michihiro ^a   Shiomi, Kazu ^a   Ishiwata, Toshiji ^a   Yoshioka, Masataka ^a   Iwase, Akihiko ^b   Iwakami, Shinichiro ^c   Yamazaki, Mariko ^a   Toba, Michie ^a   Tobino, Kazunori ^a   Sugano, Koji ^a   Ichikawa, Masako ^a   Hagiwara, Yoshiaki ^a,d   Takahashi, Kazuhisa ^a   Hino, Okio ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b JUNTENDO TOKYO KOTO GERIATRIC MEDICAL CENTER   (Japan)

^c JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^d Immuno Biological Laboratories Co Ltd   (Japan)

Author keywords

Biomarker; Mesothelin; Mesothelioma; Osteopontin

Indexed keywords

ANTIINFECTIVE AGENT; MESOTHELIN; OSTEOPONTIN; SOLUBLE MESOTHELIN RELATED PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSED IN RENAL CARCINOMA GENE; FEMALE; HUMAN; MALE; MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; TUMOR GENE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MIDDLE AGED; OSTEOPONTIN; TUMOR MARKERS, BIOLOGICAL;

EID: 58149154972     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. De Pangher Manzini V, Brollo A, Franceschi S, De Matthaeis M, Talamini R and Bianchi C: Prognostic factors of malignant mesothelioma of the pleura. Cancer 72(2): 410-417, 1993.
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C and Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14): 2636-2644, 2003.
3. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47(1): 207-214, 1981.
4. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216, 2000.
5. Monetti F, Casanova S, Grasso A, Cafferata MA, Ardizzoni A and Neumaier CE: Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases. Lung Cancer 43(1): 71-74, 2004.
6. van Klaveren RJ, Aerts JG, de Bruin H, Giaccone G, Manegold C and van Meerbeeck JP: Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 43(1): 63-69, 2004.
7. Byrne MJ and Nowak AK: Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15(2): 257-260, 2004.
8. Jain S, Bhojwani AG and Mellon JK: Improving the utility of prostate-specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers. Postgrad Med J 78(925): 646-650, 2002.
9. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I and Lu K: New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15(Suppl 3): 274-281, 2005.
10. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE and Hellstrom I: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362(9396): 1612-1616, 2003.
11. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C and Wali A: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353(15): 1564-1573, 2005.
12. Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, Copin MC, De vos P, Chahine B, Porte H and Lassalle P: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173(10): 1155-1160, 2006.
13. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Gregoire M, Porte H, Copin MC and Lassalle P: Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 13(10): 2928-2935, 2007.
14. Hino O, Kobayashi E, Nishizawa M, Kubo Y, Kobayashi T, Hirayama Y, Takai S, Kikuchi Y, Tsuchiya H, Orimoto K et al: Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol 121(9-10): 602-605, 1995.
15. Yamashita Y, Yokoyama M, Kobayashi E, Takai S and Hino O: Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun 275(1): 134-140, 2000.
16. Hassan R, Bera T and Pastan I: Mesothelin: a new target for immunotherapy. Clin Cancer Res 10(12 Pt 1): 3937-3942, 2004.
17. Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A, Maeda M, Takahashi K, Masuda K, Sakao Y and Hino O: Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 97(9): 928-932, 2006.
18. Hino O, Shiomi K and Maeda M: Diagnostic biomarker of asbestos-related mesothelioma: example of translational research. Cancer Sci 98(8): 1147-1151, 2007.
19. Shiomi K, Hagiwara Y, Sonoue K, Segawa T, Miyashita K, Maeda M, Izumi H, Masuda K, Hirabayashi M, Moriboshi T, Yoshiyama T, Ishida A, Natori Y, Inoue A, Kobayashi M, Sakao Y, Miyamoto H, Takahashi K and Hino O: Sensitive and specific-new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res 14(5): 1431-1437, 2008.
20. Takahashi F, Takahashi K, Okazaki T, Maeda K, Ienaga H, Maeda M, Kon S, Uede T and Fukuchi Y: Role of osteopontin in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 24(3): 264-271, 2001.
21. Rangaswami H, Bulbule A and Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16(2): 79-87, 2006.
22. Chang K, Pai LH, Pass H, Pogrebniak HW, Tsao MS, Pastan I and Willingham MC: Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 16(3): 259-268, 1992.
23. Chang K and Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 93(1): 136-140, 1996.
24. Ordonez NG: Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16(3): 192-197, 2003.